fluorouracil has been researched along with Encephalopathy, Toxic in 74 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We previously reported a 35% overall response rate (ORR) with biweekly 5-fluorouracil (5-FU) continuous infusion (TTD [Spanish Cooperative Group for Digestive Tumour Therapy] schedule) plus irinotecan as first-line therapy in elderly patients with metastatic colorectal cancer (mCRC)." | 9.16 | Oxaliplatin in combination with infusional 5-fluorouracil as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumors. ( Alfaro, J; Aparicio, J; Aranda, E; Benavides, M; Cabrera, E; Campos, JM; Carrato, A; Dueñas, R; Etxeberría, A; Gil-Calle, S; Gómez, A; Gómez, MJ; González-Flores, E; Guasch, I; Marcuello, E; Massutí, B; Pericay, C; Queralt, B; Reina, JJ; Valladares-Ayerbes, M, 2012) |
| " We weekly applied the orofacial section of the Acute and Chronic Neuropathy Questionnaire of Common Toxicity Criteria for Adverse Events of the National Cancer Institute of the United States of America (Oxaliplatin-specific neurotoxicity scale)." | 5.56 | FLOX (5-fluorouracil + leucovorin + oxaliplatin) chemotherapy for colorectal cancer leads to long-term orofacial neurotoxicity: a STROBE-guided longitudinal prospective study. ( Costa, BA; da Rocha Filho, DR; de Albuquerque Ribeiro Gondinho, P; de Barros Silva, PG; Gifoni, MAC; Junior, RCPL; Lima, MVA; Lisboa, MRP; Vale, ML, 2020) |
| "Capecitabine is an oral fluoropyrimidine that was designed to allow selective activation in tumour tissues, thus reducing toxicity." | 5.36 | Capecitabine-induced cerebellar toxicity in a patient with metastatic colorectal cancer. ( Ahmad, A; Gounaris, I, 2010) |
| "We previously reported a 35% overall response rate (ORR) with biweekly 5-fluorouracil (5-FU) continuous infusion (TTD [Spanish Cooperative Group for Digestive Tumour Therapy] schedule) plus irinotecan as first-line therapy in elderly patients with metastatic colorectal cancer (mCRC)." | 5.16 | Oxaliplatin in combination with infusional 5-fluorouracil as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumors. ( Alfaro, J; Aparicio, J; Aranda, E; Benavides, M; Cabrera, E; Campos, JM; Carrato, A; Dueñas, R; Etxeberría, A; Gil-Calle, S; Gómez, A; Gómez, MJ; González-Flores, E; Guasch, I; Marcuello, E; Massutí, B; Pericay, C; Queralt, B; Reina, JJ; Valladares-Ayerbes, M, 2012) |
| "Colorectal cancer patients receiving FOLFOX-4 or capecitabine plus oxaliplatin were randomized to (Arm A) calcium gluconate 1g +15% magnesium sulphate 1g diluted in 100 mL of dextrose 5% or (Arm B) placebo." | 5.14 | Use of calcium and magnesium infusions in prevention of oxaliplatin induced sensory neuropathy. ( Chay, WY; Choo, SP; Gao, F; Koo, WH; Lo, YL; Ng, HC; Ong, SY; Tan, SH, 2010) |
| "A total of 91 ACC patients received capecitabine and oxaliplatin (CAPOX) as a part of a multicentre phase-III study of the Dutch Colorectal Cancer Group." | 5.14 | Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients. ( Antonini, NF; Gelderblom, H; Guchelaar, HJ; Kweekel, DM; Nortier, JW; Punt, CJ; Van der Straaten, T, 2009) |
| "A detailed questionnaire was completed after each chemotherapy cycle for patients with metastatic colorectal cancer enrolled in a phase I trial of oxaliplatin and capecitabine." | 5.11 | Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. ( Fioravanti, S; Grem, JL; Harold, N; Leonard, GD; Quinn, MG; Schuler, B; Thomas, RR; Wright, MA, 2005) |
| " All included patients who were treated for colorectal cancer, mainly with oxaliplatin in combination with 5-fluorouracil/leucovorin." | 4.90 | A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration. ( Beijers, AJ; Mols, F; Vreugdenhil, G, 2014) |
| "In recent years, oxaliplatin-based chemotherapy protocols, particularly oxaliplatin in combination with infusional 5-fluorouracil/leucovorin (FOLFOX or FUFOX), have emerged as the standard of care in first- and second-line therapy of advanced-stage colorectal cancer." | 4.82 | Clinical management of oxaliplatin-associated neurotoxicity. ( Grothey, A, 2005) |
| " A 65-year-old man started chemotherapy for metastatic pancreatic adenocarcinoma with oxaliplatin-irinotecan-leucovorin-5-fluorouracil (FOLFIRINOX)." | 3.80 | A curious case of oxaliplatin-induced neurotoxicity: recurrent, self-limiting dysarthria. ( Dasanu, CA; Joseph, R, 2014) |
| "A total of 3359 patients with colorectal cancer treated with the FOLFOX4 regimen were included in the analyses: 1515 from 2 Asian studies (Japanese Post Marketing Surveillance and Multicenter Asia Study in Adjuvant Treatment of Colon Cancer with Oxaliplatin/5-FU/LV), and 1844 from 4 Western studies (EFC2962, N9741, EFC4584, and Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer)." | 3.78 | Safety analysis of FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies. ( André, T; Brienza, S; de Gramont, A; Goldberg, RM; Gomi, K; Lee, PH; Mizunuma, N; Ohtsu, A; Rothenberg, ML; Shimada, Y; Sugihara, K, 2012) |
| "A combination of 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX) is a standard regimen for the chemotherapy of metastatic colorectal cancer." | 3.78 | Preventive effect of traditional Japanese medicine on neurotoxicity of FOLFOX for metastatic colorectal cancer: a multicenter retrospective study. ( Ando, T; Fukuoka, J; Horikawa, N; Hosokawa, A; Kajiura, S; Kobayashi, Y; Ogawa, K; Sugiyama, T; Suzuki, N; Tsukioka, Y; Ueda, A; Yabushita, K, 2012) |
| "Oxaliplatin-associated neuropathy remains a dose-limiting toxicity of the standard chemotherapy regimen of oxaliplatin and capecitabine for metastatic colorectal cancer." | 3.76 | Heated (37 degrees C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy? ( Cathomas, R; Köberle, D; Mayer, G; Mey, U; Räss, A; Ruhstaller, T; von Moos, R, 2010) |
| "Oxaliplatin (L-OHP) in combination with infusional 5-fluorouracil/leucovorin (FOLFOX), has been established as a key drug for advanced colorectal cancer." | 3.74 | [Retrospective analysis of FOLFOX4 neurotoxicity for recovery from advanced colorectal cancer]. ( Chin, K; Hatake, K; Itimura, T; Kuboki, Y; Matsuda, M; Matsusaka, S; Mizunuma, N; Ogura, M; Suenaga, M; Syouji, D; Watanabe, C, 2008) |
| "Oxaliplatin in combination with infusional 5-fluorouracil/leucovorin (FOLFOX) have emerged as the standard of care in the therapy of advanced-stage colorectal cancer." | 3.74 | [Reduction of oxaliplatin-related neurotoxicity by calcium and magnesium infusions]. ( Akashi, T; Ando, H; Hanaoka, T; Itagaki, H; Kobayashi, Y; Muto, O; Ono, T; Onuki, M; Tanaka, Y, 2007) |
| " We report the 1st case of capecitabine-induced toxic encephalopathy with epilepsy-like symptoms and diffuse white matter alterations on magnetic resonance imaging." | 3.72 | Toxic encephalopathy induced by capecitabine. ( Herrmann, R; Niemann, B; Pless, M; Rochlitz, C, 2004) |
| " A population pharmacokinetic approach was used to determine oxaliplatin and 5-fluorouracil pharmacokinetics with and without ibudilast." | 2.94 | Ibudilast for prevention of oxaliplatin-induced acute neurotoxicity: a pilot study assessing preliminary efficacy, tolerability and pharmacokinetic interactions in patients with metastatic gastrointestinal cancer. ( Blinman, PL; Dhillon, HM; Galettis, P; McLachlan, AJ; Proschogo, N; Reuter, SE; Teng, C; Vardy, JL, 2020) |
| "Capecitabine is an anticancer drug related to 5-fluorouracil (5-FU) that is used to treat multiple cancers." | 2.82 | Reversible Toxic Encephalopathy Involving the Cerebellum and Subcortical White Matter Attributed to Capecitabine. ( Li, Y; Tang, X; Wu, X; Zhong, W, 2022) |
| "Mecobalamin combined with glutathione can significantly reduce the incidence and severity of neurotoxicity induced by FOLFOX4 chemotherapy, therefore, worthy of clinical application." | 2.82 | [Preventive effect of mecobalamin combined with glutathione on neurotoxicity induced by FOLFOX4 chemotherapy]. ( Li, SD; Li, XJ; Shi, JH, 2016) |
| "Patients with recurrent or metastatic gastric cancer diagnosed by pathology were randomly divided into two groups to receive six cycles of either the TIROX regimen (21-day cycle) or the DCF regimen (21-day cycle)." | 2.79 | Comparison of short-term efficacy and safety of TIROX and DCF regimens for advanced gastric cancer. ( Chang, ZW; Dong, L; Han, ZF; Li, J; Lou, XP; Lu, P; Miao, JH, 2014) |
| " The severity of OPN was assessed according to the Common Toxicity Criteria for Adverse Events at baseline, every 2 weeks until the 8th cycle, and every 4 weeks thereafter until the 26th week." | 2.78 | Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double‑blind, placebo‑controlled trial of goshajinkigan to prevent oxaliplatin‑induced neuropathy. ( Fukunaga, M; Hata, T; Kojima, H; Kono, T; Matsui, T; Mishima, H; Morita, S; Munemoto, Y; Nagata, N; Sakamoto, J; Shimada, M; Takemoto, H, 2013) |
| "As part of a colorectal cancer long-term survivor study (LTS-01), long-term neurotoxicity was assessed in 353 patients on NSABP Protocol C-07 (cross-sectional sample)." | 2.77 | Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01. ( Cecchini, RS; Ganz, PA; Kidwell, KM; Ko, CY; Kopec, JA; Land, SR; Wolmark, N; Yothers, G, 2012) |
| "Peripheral sensory neurotoxicity is a frequent and potentially debilitating side effect of oxaliplatin treatment." | 2.76 | The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients. ( Imholz, AL; Knijn, N; Koopman, M; Mol, L; Punt, CJ; Teerenstra, S; Tol, J; Valster, FA; Vincent, AD; Werter, MJ, 2011) |
| "The diagnosis of toxic encephalopathy was supported after elimination of alternative causes of the neurological dysfunction and complete resolution of clinical and imaging findings after 3 months of no further chemotherapy." | 2.50 | Subacute reversible toxic encephalopathy related to treatment with capecitabine: a case report with literature review and discussion of pathophysiology. ( Fassbender, K; Keller, I; Lyros, E; Papanagiotou, P; Walter, S, 2014) |
| "We describe in our report a rare case of toxic encephalopathy in a 82-year-old female, with a brief review of literature." | 2.47 | Toxic encephalopathy in elderly patients during treatment with capecitabine: literature review and a case report. ( Bagli, L; Drudi, F; Fantini, M; Gianni, L; Nicoletti, S; Possenti, C; Ravaioli, A; Sintini, M; Tamburini, E; Tassinari, D, 2011) |
| "5-Fluorouracil (5-FU) cream is a common human topical chemotherapy agent with potentially fatal neurotoxic effects on dogs if accidentally ingested." | 1.72 | Transient chemotherapy-induced alopecia after successful reversal of 5-fluorouracil myelosuppression and neurotoxicosis in a 9-month-old dog. ( Goodman, IH; Immelman, LM; Keller, N, 2022) |
| "Idiopathic hyperammonemic encephalopathy is a rare complication of chemotherapy, which has previously mainly been associated with L-asparaginase, cytarabine and 5-FU." | 1.72 | Idiopathic hyperammonemic encephalopathy secondary to gemcitabine-cisplatin treatment. ( Huitema, ADR; Otten, HM; Verkerk, K, 2022) |
| "A few days after starting the first cycle of treatment with capecitabine, a 50-year-old female with metastatic breast cancer experienced serious adverse events consisting of severe hematological, gastrointestinal and neurological toxicity." | 1.56 | Posterior reversible encephalopathy syndrome: A rare neurotoxicity after capecitabine. ( Amadori, E; Barone, D; Bartolini, G; Frassineti, GL; Monti, M; Ruscelli, S, 2020) |
| " We weekly applied the orofacial section of the Acute and Chronic Neuropathy Questionnaire of Common Toxicity Criteria for Adverse Events of the National Cancer Institute of the United States of America (Oxaliplatin-specific neurotoxicity scale)." | 1.56 | FLOX (5-fluorouracil + leucovorin + oxaliplatin) chemotherapy for colorectal cancer leads to long-term orofacial neurotoxicity: a STROBE-guided longitudinal prospective study. ( Costa, BA; da Rocha Filho, DR; de Albuquerque Ribeiro Gondinho, P; de Barros Silva, PG; Gifoni, MAC; Junior, RCPL; Lima, MVA; Lisboa, MRP; Vale, ML, 2020) |
| "Cancer chemotherapy-induced cognitive impairments are presumably associated with undesirable effects of chemotherapy on physiological functions of brain cells." | 1.51 | Adaptogens in chemobrain (Part I): Plant extracts attenuate cancer chemotherapy-induced cognitive impairment - Transcriptome-wide microarray profiles of neuroglia cells. ( Efferth, T; Klauck, SM; Panossian, A; Seo, EJ, 2019) |
| " By exclusion the pseudo-obstruction was attributed to a toxic oxaliplatin-induced autonomic neuropathy which slowly improved during months of follow-up." | 1.42 | A case of delayed oxaliplatin-induced pseudo-obstruction: an atypical presentation of oxaliplatin neurotoxicity. ( Bleecker, JD; Pauwels, W; Vandamme, M, 2015) |
| "Participants were 91 colorectal cancer patients treated with OXA-based chemotherapy." | 1.40 | Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study. ( Alberti, P; Argyriou, AA; Bergamo, F; Briani, C; Bruna, J; Cacciavillani, M; Campagnolo, M; Cavaletti, G; Cazzaniga, M; Cortinovis, D; Frigeni, B; Izquierdo, C; Kalofonos, HP; Velasco, R, 2014) |
| "Patients with colorectal cancer treated with oxaliplatin based chemotherapy (FOLFOX or XELOX) were retrospectively divided into two groups according to the use of GM1." | 1.38 | The effect of monosialotetrahexosylganglioside (GM1) in prevention of oxaliplatin induced neurotoxicity: a retrospective study. ( Chen, XF; Guo, RH; Li, J; Røe, OD; Shu, YQ; Wang, R; Wu, T; Yin, YM; Zhu, LJ, 2012) |
| "The grades of neurosensory adverse events (NSAEs) induced by FOLFOX4 treatment were compared between Asian and Western colorectal cancer patients and correlated with cumulative oxaliplatin doses." | 1.38 | Analysis of neurosensory adverse events induced by FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies. ( André, T; Brienza, S; Goldberg, RM; Gomi, K; Gramont, A; Lee, PH; Mizunuma, N; Ohtsu, A; Rothenberg, ML; Shimada, Y; Sugihara, K, 2012) |
| "5-Fluorouracil (5-FU) is a mainstay for treating various solid tumours in adults, including digestive and head and neck cancers." | 1.37 | 5-FU-induced neurotoxicity in cancer patients with profound DPD deficiency syndrome: a report of two cases. ( Ciccolini, J; Cordier, PY; Lacarelle, B; Mercier, C; Nau, A; Oliver, M; Peytel, E, 2011) |
| "Capecitabine is an oral fluoropyrimidine that was designed to allow selective activation in tumour tissues, thus reducing toxicity." | 1.36 | Capecitabine-induced cerebellar toxicity in a patient with metastatic colorectal cancer. ( Ahmad, A; Gounaris, I, 2010) |
| "Two patients with advanced gastric cancer and metastatic pancreatic cancer who received 5-fluorouracil-based chemotherapy presented with acute mental change and hyperammonemia." | 1.36 | Genetic polymorphisms associated with 5-Fluorouracil-induced neurotoxicity. ( Kim, SR; Lee, J; Lee, SY; Park, CH; Park, JO; Park, S, 2010) |
| "Capecitabine is an oral prodrug of 5-fluorouracil (5-FU) chemotherapy and is licensed for the treatment of breast and gastrointestinal cancers." | 1.35 | Encephalopathy secondary to capecitabine chemotherapy: a case report and discussion. ( Kolluri, RB; Raouf, S; Tipples, K, 2009) |
| " We have applied goshajinkigan (TJ 107) for a case of advanced colon cancer with mFOLFOX 6, and experienced a reduction in numbness, the adverse effect of LOHP." | 1.34 | [A case of neurotoxicity reduced with goshajinkigan in modified FOLFOX6 chemotherapy for advanced colon cancer]. ( Chisato, N; Ebisawa, Y; Kono, T; Mamiya, K; Mamiya, N; Satomi, M, 2007) |
| "Here, we report a case of a male with anal cancer who was treated with 5-FU 1000 mg/m(2), continuous infusion for 5 days q4 weeks." | 1.33 | Intermediate dose 5-fluorouracil-induced encephalopathy. ( Choi, HJ; Chung, HC; Jeung, HC; Kim, YA; Rha, SY; Seong, JS, 2006) |
| "Neurotoxic signs such as hyperesthesia and/or excitement, as well as convulsions, were observed in both FBAL x HCl and FA x Na groups; these toxic signs were also found in the UFT group." | 1.32 | Neurotoxic effects of alpha-fluoro-beta-alanine (FBAL) and fluoroacetic acid (FA) on dogs. ( Ariyoshi, T; Yada, H; Yamashita, K, 2004) |
| "Fluorouracil can cause both acute and delayed neurotoxicity." | 1.31 | Fluorouracil-induced neurotoxicity. ( Ali, II; Dafer, RM; Pirzada, NA, 2000) |
| "5-Fluorouracil (5-FU) is a commonly used chemotherapeutic agent." | 1.31 | A case of neurotoxicity following 5-fluorouracil-based chemotherapy. ( Han, CJ; Hong, YJ; Jeong, JM; Jeong, SH; Ki, SS; Kim, SH; Kim, YC; Lee, JH; Lee, JO, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 22 (29.73) | 29.6817 |
| 2010's | 43 (58.11) | 24.3611 |
| 2020's | 9 (12.16) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Y | 1 |
| Wu, X | 1 |
| Zhong, W | 1 |
| Tang, X | 1 |
| Immelman, LM | 1 |
| Goodman, IH | 1 |
| Keller, N | 1 |
| Verkerk, K | 1 |
| Otten, HM | 1 |
| Huitema, ADR | 1 |
| Chiu, YW | 1 |
| Tsui, YK | 1 |
| Shen, HN | 1 |
| Monti, M | 1 |
| Barone, D | 1 |
| Amadori, E | 1 |
| Bartolini, G | 1 |
| Ruscelli, S | 1 |
| Frassineti, GL | 1 |
| de Albuquerque Ribeiro Gondinho, P | 1 |
| de Barros Silva, PG | 1 |
| Lisboa, MRP | 1 |
| Costa, BA | 1 |
| da Rocha Filho, DR | 1 |
| Gifoni, MAC | 1 |
| Lima, MVA | 1 |
| Junior, RCPL | 1 |
| Vale, ML | 1 |
| Teng, C | 1 |
| Reuter, SE | 1 |
| Blinman, PL | 1 |
| Dhillon, HM | 1 |
| Galettis, P | 1 |
| Proschogo, N | 1 |
| McLachlan, AJ | 1 |
| Vardy, JL | 1 |
| Takeshita, E | 1 |
| Ishibashi, K | 2 |
| Koda, K | 1 |
| Oda, N | 1 |
| Yoshimatsu, K | 1 |
| Sato, Y | 1 |
| Oya, M | 1 |
| Yamaguchi, S | 1 |
| Nakajima, H | 1 |
| Momma, T | 1 |
| Maekawa, H | 1 |
| Tsubaki, M | 1 |
| Yamada, T | 1 |
| Kobayashi, M | 1 |
| Tanakaya, K | 1 |
| Ishida, H | 2 |
| Gui, Q | 1 |
| Li, D | 1 |
| Zhuge, Y | 1 |
| Xu, C | 1 |
| Acharya, G | 1 |
| Cruz Carreras, MT | 1 |
| Rice, TW | 1 |
| Anon, B | 1 |
| Largeau, B | 1 |
| Girault, A | 1 |
| Chantome, A | 1 |
| Caulet, M | 1 |
| Perray, C | 1 |
| Moussata, D | 1 |
| Vandier, C | 1 |
| Barin-Le Guellec, C | 1 |
| Lecomte, T | 1 |
| Seo, EJ | 1 |
| Klauck, SM | 1 |
| Efferth, T | 1 |
| Panossian, A | 1 |
| Argyriou, AA | 4 |
| Cavaletti, G | 4 |
| Antonacopoulou, A | 1 |
| Genazzani, AA | 1 |
| Briani, C | 4 |
| Bruna, J | 4 |
| Terrazzino, S | 1 |
| Velasco, R | 4 |
| Alberti, P | 4 |
| Campagnolo, M | 2 |
| Lonardi, S | 4 |
| Cortinovis, D | 4 |
| Cazzaniga, M | 4 |
| Santos, C | 2 |
| Psaromyalou, A | 1 |
| Angelopoulou, A | 1 |
| Kalofonos, HP | 4 |
| Joseph, R | 1 |
| Dasanu, CA | 1 |
| Kono, T | 3 |
| Hata, T | 1 |
| Morita, S | 2 |
| Munemoto, Y | 1 |
| Matsui, T | 1 |
| Kojima, H | 1 |
| Takemoto, H | 1 |
| Fukunaga, M | 1 |
| Nagata, N | 1 |
| Shimada, M | 2 |
| Sakamoto, J | 2 |
| Mishima, H | 2 |
| Barrueco, N | 1 |
| Such Díaz, A | 1 |
| Sáez de la Fuente, J | 1 |
| Escobar, I | 1 |
| Lyros, E | 1 |
| Walter, S | 1 |
| Keller, I | 1 |
| Papanagiotou, P | 1 |
| Fassbender, K | 1 |
| Dong, L | 1 |
| Li, J | 2 |
| Lou, XP | 1 |
| Miao, JH | 1 |
| Lu, P | 1 |
| Chang, ZW | 1 |
| Han, ZF | 1 |
| Beijers, AJ | 1 |
| Mols, F | 1 |
| Vreugdenhil, G | 1 |
| Peddi, PF | 1 |
| Peddi, S | 1 |
| Santos, ES | 1 |
| Morgensztern, D | 1 |
| Vandamme, M | 1 |
| Pauwels, W | 1 |
| Bleecker, JD | 1 |
| Izquierdo, C | 1 |
| Frigeni, B | 1 |
| Cacciavillani, M | 2 |
| Bergamo, F | 2 |
| Pachman, DR | 1 |
| Qin, R | 1 |
| Seisler, DK | 1 |
| Smith, EM | 1 |
| Beutler, AS | 1 |
| Ta, LE | 1 |
| Lafky, JM | 1 |
| Wagner-Johnston, ND | 1 |
| Ruddy, KJ | 1 |
| Dakhil, S | 1 |
| Staff, NP | 1 |
| Grothey, A | 2 |
| Loprinzi, CL | 1 |
| Li, SD | 1 |
| Shi, JH | 1 |
| Li, XJ | 1 |
| Tsuruta, A | 1 |
| Yamashita, K | 2 |
| Tanioka, H | 1 |
| Tsuji, A | 1 |
| Inukai, M | 1 |
| Yamakawa, T | 1 |
| Yamatsuji, T | 1 |
| Yoshimitsu, M | 1 |
| Toyota, K | 1 |
| Yamano, T | 1 |
| Nagasaka, T | 1 |
| Okajima, M | 1 |
| Gandal, MJ | 1 |
| Ehrlichman, RS | 1 |
| Rudnick, ND | 1 |
| Siegel, SJ | 1 |
| Kweekel, DM | 1 |
| Gelderblom, H | 1 |
| Antonini, NF | 1 |
| Van der Straaten, T | 1 |
| Nortier, JW | 1 |
| Punt, CJ | 2 |
| Guchelaar, HJ | 1 |
| Tipples, K | 1 |
| Kolluri, RB | 1 |
| Raouf, S | 1 |
| Cathomas, R | 1 |
| Köberle, D | 1 |
| Ruhstaller, T | 1 |
| Mayer, G | 1 |
| Räss, A | 1 |
| Mey, U | 1 |
| von Moos, R | 1 |
| Gounaris, I | 1 |
| Ahmad, A | 1 |
| Chen, YC | 1 |
| Tzeng, CH | 1 |
| Chen, PM | 1 |
| Lin, JK | 2 |
| Lin, TC | 1 |
| Chen, WS | 1 |
| Jiang, JK | 2 |
| Wang, HS | 1 |
| Wang, WS | 1 |
| Uña, E | 1 |
| Okada, N | 1 |
| Miyazaki, T | 1 |
| Sano, M | 1 |
| Matsuo, K | 1 |
| Higuchi, M | 1 |
| Sasaki, Y | 1 |
| Iwatsubo, S | 1 |
| Wada, Y | 1 |
| Hasegawa, K | 1 |
| Shirakawa, A | 1 |
| Mishima, K | 1 |
| Iwasaki, K | 1 |
| Fujiwara, M | 1 |
| Nishino, H | 1 |
| Dong, M | 1 |
| Xing, PY | 1 |
| Liu, P | 1 |
| Feng, FY | 1 |
| Shi, YK | 1 |
| Saif, MW | 1 |
| Syrigos, K | 1 |
| Kaley, K | 1 |
| Isufi, I | 1 |
| Kim, SR | 1 |
| Park, CH | 1 |
| Park, S | 1 |
| Park, JO | 1 |
| Lee, J | 1 |
| Lee, SY | 1 |
| Hill, A | 1 |
| Bergin, P | 1 |
| Hanning, F | 1 |
| Thompson, P | 1 |
| Findlay, M | 1 |
| Damianovich, D | 1 |
| McKeage, MJ | 1 |
| Fantini, M | 1 |
| Gianni, L | 1 |
| Tassinari, D | 1 |
| Nicoletti, S | 1 |
| Possenti, C | 1 |
| Drudi, F | 1 |
| Sintini, M | 1 |
| Bagli, L | 1 |
| Tamburini, E | 1 |
| Ravaioli, A | 1 |
| Knijn, N | 1 |
| Tol, J | 1 |
| Koopman, M | 1 |
| Werter, MJ | 1 |
| Imholz, AL | 1 |
| Valster, FA | 1 |
| Mol, L | 1 |
| Vincent, AD | 1 |
| Teerenstra, S | 1 |
| Chay, WY | 1 |
| Tan, SH | 1 |
| Lo, YL | 1 |
| Ong, SY | 1 |
| Ng, HC | 1 |
| Gao, F | 1 |
| Koo, WH | 1 |
| Choo, SP | 1 |
| Park, SB | 1 |
| Lin, CS | 1 |
| Krishnan, AV | 1 |
| Goldstein, D | 1 |
| Friedlander, ML | 1 |
| Kiernan, MC | 1 |
| Cordier, PY | 1 |
| Nau, A | 1 |
| Ciccolini, J | 1 |
| Oliver, M | 1 |
| Mercier, C | 1 |
| Lacarelle, B | 1 |
| Peytel, E | 1 |
| Sugihara, K | 2 |
| Ohtsu, A | 2 |
| Shimada, Y | 2 |
| Mizunuma, N | 3 |
| Lee, PH | 2 |
| de Gramont, A | 1 |
| Goldberg, RM | 2 |
| Rothenberg, ML | 2 |
| André, T | 2 |
| Brienza, S | 2 |
| Gomi, K | 2 |
| Chang, YY | 1 |
| Chen, XF | 1 |
| Wang, R | 1 |
| Yin, YM | 1 |
| Røe, OD | 1 |
| Zhu, LJ | 1 |
| Guo, RH | 1 |
| Wu, T | 1 |
| Shu, YQ | 1 |
| Benavides, M | 1 |
| Pericay, C | 1 |
| Valladares-Ayerbes, M | 1 |
| Gil-Calle, S | 1 |
| Massutí, B | 1 |
| Aparicio, J | 1 |
| Dueñas, R | 1 |
| González-Flores, E | 1 |
| Carrato, A | 1 |
| Marcuello, E | 1 |
| Gómez, A | 1 |
| Cabrera, E | 1 |
| Queralt, B | 1 |
| Gómez, MJ | 1 |
| Guasch, I | 1 |
| Etxeberría, A | 1 |
| Alfaro, J | 1 |
| Campos, JM | 1 |
| Reina, JJ | 1 |
| Aranda, E | 1 |
| Kidwell, KM | 1 |
| Yothers, G | 1 |
| Ganz, PA | 1 |
| Land, SR | 1 |
| Ko, CY | 1 |
| Cecchini, RS | 1 |
| Kopec, JA | 1 |
| Wolmark, N | 1 |
| Hosokawa, A | 1 |
| Ogawa, K | 1 |
| Ando, T | 1 |
| Suzuki, N | 1 |
| Ueda, A | 1 |
| Kajiura, S | 1 |
| Kobayashi, Y | 2 |
| Tsukioka, Y | 1 |
| Horikawa, N | 1 |
| Yabushita, K | 1 |
| Fukuoka, J | 1 |
| Sugiyama, T | 1 |
| Cecchin, E | 1 |
| D'Andrea, M | 1 |
| Zanusso, C | 1 |
| Pella, N | 1 |
| Errante, D | 1 |
| De Mattia, E | 1 |
| Polesel, J | 1 |
| Innocenti, F | 1 |
| Toffoli, G | 1 |
| Martinez-Lapiscina, EH | 1 |
| Erro, ME | 1 |
| Cabada, T | 1 |
| Tuñón, T | 1 |
| Lucchetta, M | 1 |
| Gramont, A | 1 |
| Zhu, Y | 1 |
| Yang, J | 1 |
| Jiao, S | 1 |
| Ji, T | 1 |
| Yada, H | 1 |
| Ariyoshi, T | 1 |
| Niemann, B | 1 |
| Rochlitz, C | 1 |
| Herrmann, R | 1 |
| Pless, M | 1 |
| Elkiran, ET | 1 |
| Altundag, K | 1 |
| Beyazit, Y | 1 |
| Guler, N | 1 |
| Kars, A | 1 |
| Correale, P | 1 |
| Fulfaro, F | 1 |
| Marsili, S | 2 |
| Cicero, G | 1 |
| Bajardi, E | 1 |
| Intrivici, C | 1 |
| Vuolo, G | 1 |
| Carli, AF | 1 |
| Caraglia, M | 1 |
| Del Prete, S | 1 |
| Greco, E | 1 |
| Gebbia, N | 1 |
| Francini, G | 2 |
| Leonard, GD | 1 |
| Wright, MA | 1 |
| Quinn, MG | 1 |
| Fioravanti, S | 1 |
| Harold, N | 1 |
| Schuler, B | 1 |
| Thomas, RR | 1 |
| Grem, JL | 1 |
| Kreukels, BP | 1 |
| Schagen, SB | 1 |
| Ridderinkhof, KR | 1 |
| Boogerd, W | 1 |
| Hamburger, HL | 1 |
| van Dam, FS | 1 |
| Videnovic, A | 1 |
| Semenov, I | 1 |
| Chua-Adajar, R | 1 |
| Baddi, L | 1 |
| Blumenthal, DT | 1 |
| Beck, AC | 1 |
| Simuni, T | 1 |
| Futterer, S | 1 |
| Gradishar, W | 1 |
| Tellez, C | 1 |
| Raizer, JJ | 1 |
| Kim, YA | 1 |
| Chung, HC | 1 |
| Choi, HJ | 1 |
| Rha, SY | 1 |
| Seong, JS | 1 |
| Jeung, HC | 1 |
| Lucato, LT | 1 |
| McKinney, AM | 1 |
| Short, J | 1 |
| Teksam, M | 1 |
| Truwit, CL | 1 |
| Petrioli, R | 1 |
| Pascucci, A | 1 |
| Francini, E | 1 |
| Sciandivasci, A | 1 |
| Tassi, R | 1 |
| Civitelli, S | 1 |
| Tanzini, G | 1 |
| Lorenzi, M | 1 |
| Muto, O | 1 |
| Ando, H | 1 |
| Ono, T | 1 |
| Itagaki, H | 1 |
| Onuki, M | 1 |
| Akashi, T | 1 |
| Tanaka, Y | 1 |
| Hanaoka, T | 1 |
| Mamiya, N | 1 |
| Mamiya, K | 1 |
| Satomi, M | 1 |
| Chisato, N | 1 |
| Ebisawa, Y | 1 |
| Matsuda, M | 1 |
| Matsusaka, S | 1 |
| Kuboki, Y | 1 |
| Itimura, T | 1 |
| Ogura, M | 1 |
| Suenaga, M | 1 |
| Syouji, D | 1 |
| Watanabe, C | 1 |
| Chin, K | 1 |
| Hatake, K | 1 |
| Pirzada, NA | 1 |
| Ali, II | 1 |
| Dafer, RM | 1 |
| Haller, DG | 1 |
| Serrano-Castro, PJ | 1 |
| Aguilar-Castillo, MJ | 1 |
| Ki, SS | 1 |
| Jeong, JM | 1 |
| Kim, SH | 1 |
| Jeong, SH | 1 |
| Lee, JH | 1 |
| Han, CJ | 1 |
| Kim, YC | 1 |
| Lee, JO | 1 |
| Hong, YJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of High Tone Therapy and TENS Therapy in Chemotherapy-induced Polyneuropathy[NCT03978585] | 51 participants (Actual) | Interventional | 2019-09-03 | Completed | |||
| A Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium/Magnesium to Prevent Oxaliplatin-Induced Sensory Neurotoxicity[NCT00316914] | Phase 3 | 104 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| The Possible Protective Effect of Pentoxifylline Against Chemotherapy Induced Toxicities in Patients With Colorectal Cancer[NCT05590117] | Early Phase 1 | 48 participants (Anticipated) | Interventional | 2022-10-11 | Enrolling by invitation | ||
| The Effect of ATP-Binding Cassette C2 (ABCC2) Transporter Genetic Polymorphism on Neurotoxicity in Gastrointestinal Cancer Patients Receiving Oxaliplatin -Based Chemotherapy[NCT05494320] | 120 participants (Anticipated) | Observational | 2021-08-15 | Recruiting | |||
| Chemotherapy-Related Changes in Neurocognitive Function and Symptoms in Colorectal Cancer Patients: A Pilot Study[NCT03683004] | 40 participants (Actual) | Observational | 2018-01-22 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Neuropathic adverse events were assessed by CTCAE v3.0. (NCT00316914)
Timeframe: 127 days
| Intervention | days (Median) |
|---|---|
| Ca/Mg | 81 |
| Placebo | 72 |
Neurotoxicity were assessed by CTCAE v3.0. (NCT00316914)
Timeframe: 127 days
| Intervention | Percentage of Participants (Number) |
|---|---|
| Ca/Mg | 46 |
| Placebo | 55.8 |
Acute neuropathic toxicities were measured using the Symptom Experience Diary and supplemental quality of life questions in the scale of 0 (no symptom) to 10 (worst symptom). The item score was reversed and transformed into 0 (low QOL) to 100 (best QOL) scale for analysis. Any score greater than 0 was considered having acute neuropathy. (NCT00316914)
Timeframe: 127 days
| Intervention | Percentage of participants (Number) |
|---|---|
| Ca/Mg | 88 |
| Placebo | 90 |
Neuropathic adverse events were assessed by Common Terminology Criteria for Adverse Events (CTCAE) v3.0. Neurotoxicity evaluation grade: loss of deep tendon reflexes or paresthesia, including tingling, but not interfering with function (Grade 1); objective sensory alteration or paresthesia, including tingling, interfering with function, but not with activities of daily living (Grade 2); sensory alteration or paresthesia interfering with activities of daily living (Grade 3); permanent sensory losses that are disabling (Grade 4) (NCT00316914)
Timeframe: 127 days
| Intervention | Percentage of participants (Number) |
|---|---|
| Ca/Mg | 22 |
| Placebo | 41 |
Neurotoxicity were assessed by Common Terminology Criteria for Adverse Events (CTCAE) v3.0. (NCT00316914)
Timeframe: 127 days
| Intervention | Days (Median) |
|---|---|
| Ca/Mg | NA |
| Placebo | 18.1 |
Neurotoxicity was assessed by CTCAE v3.0. (NCT00316914)
Timeframe: 127 days
| Intervention | Days (Median) |
|---|---|
| Ca/Mg | NA |
| Placebo | NA |
Fatigue was measured by Brief Fatigue Inventory in the scale of 0 (no fatigue) to 10 (fatigue as bad as you can imagine). The item score was reversed and transformed into 0 (low quality of life (QOL)) to 100 (best QOL) scale for analysis. Change: score at one month minus score at baseline. (NCT00316914)
Timeframe: Baseline and One month
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Fatigue NOW | Fatigue USUAL | Fatigue WORST | |
| Ca/Mg | 1.0 | 3.1 | 0.0 |
| Placebo | -2.8 | -1.6 | -1.6 |
Quality of Life (QOL) were measured using the Symptom Experience Diary and supplemental quality of life questions. Item score range: 0 (no symptom) to 10 (worst symptom). The score was reversed and transformed into 0 (low QOL) to 100 (best QOL) scale for analysis. Change: score at one month minus score at baseline. (NCT00316914)
Timeframe: Baseline and One month
| Intervention | Units on a scale (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fatigue WORST | Walking | Buttoning Shirt or Tying Laces | Diarrhea | Constipation | Abdominal Cramping | Bowel Problems with Normal Activity | Shortness of Breath (Week 2 - Baseline) | Swallowing (Week 2 - Baseline) | Numbness in Fingers, Toes (Week 2 - Baseline) | Tingling in Fingers, Toes (Week 2 - Baseline) | |
| Ca/Mg | 0.0 | -2.5 | -2.0 | -7.1 | -2.9 | -2.5 | -3.2 | -0.7 | -7.5 | -8.3 | -14.8 |
| Placebo | -1.6 | 0.2 | 0.4 | -10.4 | 0.4 | 1.3 | -9.1 | 2.1 | 2.1 | -9.6 | -20.4 |
Adverse Events were measured using CTCAE V3.0. (NCT00316914)
Timeframe: 127 days
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abdominal Infection | Acne NOS | Anemia | Anorexia | Clostridial Infection | Constipation | Dehydration | Diarrhea-No Colostom | Dry Skin | Erythema Multiforme | Fatigue | Hypercalcemia | Hyperglycemia | Hypermagnesemia | Hypersensitivity | Hypokalemia | Hypomagnesemia | Hyponatremia | Infection | Ischemia-Cerebral | Ischemia/Infarction | Laryngeal Discomfort | Leukopenia | Muscle Weakness | Myalgia | Nausea | Neuro-motor | Neuro-sensory | Neutropenia | Oral cavity MS CE | Pain-Abdominal | Pain-Chest | Pain-Headache | Rash/Desquamation | Skin Rxn-Hand/Foot | Stomatitis | Taste | Thrombocytopenia | Thrombosis | Urticaria | Vasc Access Complication | Vomiting | |
| Ca/Mg | 2 | 2 | 4 | 4 | 0 | 42 | 2 | 68 | 0 | 4 | 10 | 0 | 2 | 14 | 6 | 4 | 0 | 4 | 0 | 0 | 2 | 0 | 6 | 2 | 4 | 60 | 4 | 2 | 18 | 2 | 0 | 0 | 0 | 4 | 4 | 2 | 2 | 2 | 6 | 0 | 2 | 34 |
| Placebo | 0 | 2 | 4 | 2 | 2 | 47 | 6 | 73 | 2 | 0 | 25 | 2 | 0 | 18 | 0 | 2 | 2 | 0 | 2 | 2 | 0 | 2 | 10 | 0 | 0 | 71 | 4 | 12 | 33 | 0 | 8 | 2 | 4 | 0 | 2 | 2 | 2 | 2 | 4 | 2 | 0 | 33 |
7 reviews available for fluorouracil and Encephalopathy, Toxic
| Article | Year |
|---|---|
Reversible Toxic Encephalopathy Involving the Cerebellum and Subcortical White Matter Attributed to Capecitabine.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Cerebellum; Fluorouracil; Humans; Neurotoxicity Syndr | 2022 |
Subacute reversible toxic encephalopathy related to treatment with capecitabine: a case report with literature review and discussion of pathophysiology.
Topics: Aged; Brain Edema; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Magnetic Resonance Imaging; Ma | 2014 |
A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor | 2014 |
Central nervous system toxicities of chemotherapeutic agents.
Topics: Antineoplastic Agents; Central Nervous System Diseases; Cisplatin; Cytarabine; Fluorouracil; Humans; | 2014 |
Toxic encephalopathy in elderly patients during treatment with capecitabine: literature review and a case report.
Topics: Adenocarcinoma; Age Factors; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Cap | 2011 |
Clinical management of oxaliplatin-associated neurotoxicity.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorou | 2005 |
Safety of oxaliplatin in the treatment of colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, | 2000 |
20 trials available for fluorouracil and Encephalopathy, Toxic
| Article | Year |
|---|---|
Ibudilast for prevention of oxaliplatin-induced acute neurotoxicity: a pilot study assessing preliminary efficacy, tolerability and pharmacokinetic interactions in patients with metastatic gastrointestinal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Interactions; Female; Fluorouracil; Gastr | 2020 |
Efficacy of Exercise Rehabilitation Program in Relieving Oxaliplatin Induced Peripheral Neurotoxicity.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Digestiv | 2021 |
Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double‑blind, placebo‑controlled trial of goshajinkigan to prevent oxaliplatin‑induced neuropathy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2013 |
Comparison of short-term efficacy and safety of TIROX and DCF regimens for advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docet | 2014 |
Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance).
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Calcium Compounds; Chronic Disease; C | 2015 |
[Preventive effect of mecobalamin combined with glutathione on neurotoxicity induced by FOLFOX4 chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Glutathione; Humans; Leucovorin; Neuro | 2016 |
Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2016 |
Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Codon; | 2009 |
Preventive effect of goshajinkigan on peripheral neurotoxicity of FOLFOX therapy: a placebo-controlled double-blind randomized phase II study (the GONE Study).
Topics: Adolescent; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; | 2009 |
Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: a prospective randomized study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Calcium; Colorectal Neoplasms; Drug Administration S | 2010 |
[Assessment of the protective effect of calcium-magnesium infusion and glutathione on oxaliplatin-induced neurotoxicity].
Topics: Adolescent; Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Calcium Gl | 2010 |
The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2011 |
Use of calcium and magnesium infusions in prevention of oxaliplatin induced sensory neuropathy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Calcium Gluconate; Capecita | 2010 |
Oxaliplatin in combination with infusional 5-fluorouracil as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diabe | 2012 |
Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01.
Topics: Adult; Aged; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; | 2012 |
Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colore | 2012 |
Ganglioside-monosialic acid (GM1) prevents oxaliplatin-induced peripheral neurotoxicity in patients with gastrointestinal tumors.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Co | 2013 |
Gemcitabine (GEM) plus oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX-4) in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2005 |
Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Clinical Trials a | 2005 |
Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dose- | 2008 |
47 other studies available for fluorouracil and Encephalopathy, Toxic
| Article | Year |
|---|---|
Transient chemotherapy-induced alopecia after successful reversal of 5-fluorouracil myelosuppression and neurotoxicosis in a 9-month-old dog.
Topics: Aftercare; Alopecia Areata; Animals; Antineoplastic Agents; Dog Diseases; Dogs; Female; Fluorouracil | 2022 |
Idiopathic hyperammonemic encephalopathy secondary to gemcitabine-cisplatin treatment.
Topics: Antineoplastic Agents; Asparaginase; Brain Diseases; Cisplatin; Cytarabine; Deoxycytidine; Fluoroura | 2022 |
Reversible cerebral edema and herniation caused by 5-fluorouracil-induced hyperammonemic encephalopathy.
Topics: Brain Edema; Fluorouracil; Humans; Hyperammonemia; Neurotoxicity Syndromes | 2023 |
Posterior reversible encephalopathy syndrome: A rare neurotoxicity after capecitabine.
Topics: Capecitabine; Female; Fluorouracil; Humans; Magnetic Resonance Imaging; Middle Aged; Neurotoxicity S | 2020 |
FLOX (5-fluorouracil + leucovorin + oxaliplatin) chemotherapy for colorectal cancer leads to long-term orofacial neurotoxicity: a STROBE-guided longitudinal prospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2020 |
The updated five-year overall survival and long-term oxaliplatin-related neurotoxicity assessment of the FACOS study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Ad | 2021 |
5-FU-induced leukoencephalopathy with reversible lesion of splenium of corpus callosum in a patient with colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Corpus Callosum; Fluorouracil; Humans; | 2017 |
Possible association of CAG repeat polymorphism in KCNN3 encoding the potassium channel SK3 with oxaliplatin-induced neurotoxicity.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorour | 2018 |
Adaptogens in chemobrain (Part I): Plant extracts attenuate cancer chemotherapy-induced cognitive impairment - Transcriptome-wide microarray profiles of neuroglia cells.
Topics: Andrographis; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cognitive Dysfunction; Cycl | 2019 |
Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxyc | 2013 |
A curious case of oxaliplatin-induced neurotoxicity: recurrent, self-limiting dysarthria.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administrat | 2014 |
[Hyperammonemic encephalopathy in a patient treated with 5-fluorouracil].
Topics: Adenocarcinoma; Antimetabolites; Fluorouracil; Humans; Hyperammonemia; Lung Neoplasms; Male; Middle | 2014 |
A case of delayed oxaliplatin-induced pseudo-obstruction: an atypical presentation of oxaliplatin neurotoxicity.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colecto | 2015 |
Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Co | 2014 |
A novel electrophysiological model of chemotherapy-induced cognitive impairments in mice.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Auditory Perception; Cognition Diso | 2008 |
Encephalopathy secondary to capecitabine chemotherapy: a case report and discussion.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; | 2009 |
Heated (37 degrees C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colore | 2010 |
Capecitabine-induced cerebellar toxicity in a patient with metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecit | 2010 |
Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 2010 |
Atypical presentation of acute neurotoxicity secondary to oxaliplatin.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2010 |
[Analysis of a case of oxaliplatin - induced persistence sensory neuropathy].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopl | 2010 |
Role of pregabalin in treatment of oxaliplatin-induced sensory neuropathy.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycyti | 2010 |
Genetic polymorphisms associated with 5-Fluorouracil-induced neurotoxicity.
Topics: Antimetabolites, Antineoplastic; Female; Fluorouracil; Genotype; Humans; Male; Middle Aged; Neurotox | 2010 |
Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Cisplatin; C | 2010 |
Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; De | 2011 |
5-FU-induced neurotoxicity in cancer patients with profound DPD deficiency syndrome: a report of two cases.
Topics: Aged; Antimetabolites, Antineoplastic; Brain; Dihydropyrimidine Dehydrogenase Deficiency; Electroenc | 2011 |
Safety analysis of FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asia; Australia; Canada; Clinical Trials as Topic; C | 2012 |
Oxaliplatin-related hyperammonaemic encephalopathy in a patient with colon cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neopl | 2012 |
The effect of monosialotetrahexosylganglioside (GM1) in prevention of oxaliplatin induced neurotoxicity: a retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo | 2012 |
Preventive effect of traditional Japanese medicine on neurotoxicity of FOLFOX for metastatic colorectal cancer: a multicenter retrospective study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2012 |
A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2013 |
5-Fluorouracil induced hyperammonemic encephalophathy: etiopathologic correlation.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Brain Neoplasms; Diffusion Magnetic Resonance Imagi | 2012 |
Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer.
Topics: Acute Disease; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecita | 2012 |
Analysis of neurosensory adverse events induced by FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Colorectal Neoplasms; Female; Fl | 2012 |
Neurotoxic effects of alpha-fluoro-beta-alanine (FBAL) and fluoroacetic acid (FA) on dogs.
Topics: Administration, Oral; Animals; beta-Alanine; Dogs; Fluoroacetates; Fluorouracil; Hyperesthesia; Male | 2004 |
Toxic encephalopathy induced by capecitabine.
Topics: Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Epil | 2004 |
Fluorouracil-induced neurotoxicity presenting with generalized tonic-clonic seizure.
Topics: Adenocarcinoma; Anticonvulsants; Antimetabolites, Antineoplastic; Fluorouracil; Humans; Male; Middle | 2004 |
Electrophysiological correlates of information processing in breast-cancer patients treated with adjuvant chemotherapy.
Topics: Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Case- | 2005 |
Capecitabine-induced multifocal leukoencephalopathy: a report of five cases.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Brain; Breast Neoplasms; Capecitabine; Carcinoma; Deox | 2005 |
Intermediate dose 5-fluorouracil-induced encephalopathy.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasm | 2006 |
Reversible findings of restricted diffusion in 5-fluorouracil neurotoxicity.
Topics: Adult; Antimetabolites, Antineoplastic; Anus Neoplasms; Carcinoma, Squamous Cell; Corpus Callosum; F | 2006 |
[Reduction of oxaliplatin-related neurotoxicity by calcium and magnesium infusions].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Calcium; Colorectal Neoplas | 2007 |
[A case of neurotoxicity reduced with goshajinkigan in modified FOLFOX6 chemotherapy for advanced colon cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administrati | 2007 |
[Retrospective analysis of FOLFOX4 neurotoxicity for recovery from advanced colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel | 2008 |
Fluorouracil-induced neurotoxicity.
Topics: Aged; Antimetabolites, Antineoplastic; Ataxia; Confusion; Esophageal Neoplasms; Fluorouracil; Humans | 2000 |
Comment: fluorouracil-induced aphasia: neurotoxicity versus cerebral ischemia.
Topics: Adult; Antimetabolites; Aphasia; Brain Ischemia; Fluorouracil; Humans; Male; Neurotoxicity Syndromes | 2001 |
A case of neurotoxicity following 5-fluorouracil-based chemotherapy.
Topics: Adult; Brain; Electroencephalography; Fluorouracil; Gastrointestinal Neoplasms; Humans; Leukoencepha | 2002 |